On5, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or ...
Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight ...
Phosphoric acid, a widely used chemical compound, presents a nuanced case when classified as a strong or weak acid. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback